Alpha Cognition Inc. Common Stock (NASDAQ:ACOG) Q1 2026 Earnings Call Transcript

Alpha Cognition Inc. Common Stock (NASDAQ:ACOG) Q1 2026 Earnings Call Transcript May 14, 2026

Alpha Cognition Inc. Common Stock beats earnings expectations. Reported EPS is $-0.37, expectations were $-0.41.

Operator: Greetings, and welcome to the Alpha Cognition First Quarter Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Henry Du, Interim CFO. You may begin.

Henry Du: Thanks, Kate. Good afternoon, everyone, and thank you for joining us today for Alpha Cognition’s first quarter 2026 financial results conference call. Today, after the close of market, the company issued a press release announcing these results. On the call with me today are Alpha Cognition’s, Chief Executive Officer, Michael McFadden, and Chief Operating Officer, Lauren D’Angelo. Today’s call is being made available via the Investors section of the company’s website at www.alphacognition.com. During the course of this call, management may make certain forward-looking statements regarding future events and the company’s future performance. These forward-looking statements reflect Alpha Cognition’s current perspective on existing trends and information.

Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those noted in the Risk Factors section of the company’s latest SEC filings. Actual results may differ materially from those projected in these forward-looking statements. For the benefit of those of you who may be listening to the replay, this call is being held and recorded on May 14, 2026. Since then, the company may have made additional announcements related to the topics discussed. Please reference the company’s most recent press releases and current filings with the SEC. Alpha Cognition declines any obligation to update these forward-looking statements, except as required by applicable securities laws. I’ll now turn the call over to Michael.

Michael?

Michael McFadden: Thank you, Henry. Good afternoon, everyone, and welcome to today’s call. The first quarter of 2026 represents our fourth full quarter of commercialization for ZUNVEYL the first new oral Alzheimer’s treatment approved in more than 15 years and the quarter was a strong one. We delivered 40% quarter-over-quarter revenue growth, acceleration and prescriber adoption advanced strategic priorities across our clinical programs. We strengthened our intellectual property portfolio and the company further built out our organization as we enter the expansion phase for ZUNVEYL. We continue to execute with discipline and confidence, and I believe this quarter demonstrates that ZUNVEYL’s commercial story is tracking well with our internal expectations.

In Q1 2026, we generated net total product revenues of $3.5 million, a 40% sequential increase over Q4 2025. While we are very pleased with ZUNVEYL’s trajectory, we’re still at only the start of ZUNVEYL’s commercial phase. The company remains optimistic and believe we will continue to see signs of sustained product performance and adoption within the long-term care segment. Looking at Q1, we saw growth in the quarter with March delivering our strongest month of demand sales and April is stronger than March. Overall, we believe we’re on track with our 2026 strategic priorities and we continue to expect to achieve operating profitability in 2027. On the adoption side, our prescription KPIs remained strong. Our bottles dispensed grew 23% over Q4.

Our HCP riders grew 23% over year-end 2025, and we’re on track to achieve our 2026 goal of approximately 2,000 prescribers. Our call down prescribers expanded 93% quarter-over-quarter and our nursing homes with ZUNVEYL prescriptions grew 25%. Additionally, the commercial team built out a 60-person customer-facing team in the quarter. We saw an added experienced marketing and payer engagement capabilities to the team. And last month, we strengthened our Board of Directors with the addition of a new independent Board member, Bethany Cincinnati. We look to her experience to help build out Alpha cognition strategy and for her to provide financial governance for the company. Turning to our clinical programs. We have 3 active real-world studies underway, which we believe will strengthen ZUNVEYL’s positioning with payer and health care providers.

Beacon, our real-world effectiveness study evaluating ZUNVEYL and long-term care residents with Alzheimer’s disease will complete enrollment this quarter. The company will report top line data from Beacon no later than early third quarter, an acceleration from our prior expectation of late Q4. CONVERGE, our retrospective data analysis evaluating tolerability, dosing, polypharmacy and adverse events and long-term care initiates in Q2 as planned and we expect top line data from this trial in Q3 of 2026. We expect both Beacon and CONVERGE to provide the company numerous publication opportunities over the coming year. RESOLVE our Phase IV outpatient study will also initiate this quarter. This study will provide additional data regarding tolerability and efficacy and treating behaviors associated with Alzheimer’s disease in the outpatient setting.

On the intellectual property front, the U.S. at an office issued 2 patents to provide additional protection for ZUNVEYL, a new patent covering dosage regimens for bensalantamine was given in February and a second covering the use of bensglantomine for treating traumatic brain injury was issued in March. Both patents extend protection of the product through 2045. And the TBI market, by the way, represents an addressable opportunity for the company estimated at approximately $14 billion. Regarding our sublingual formulation program, we will initiate a comparative pharmacokinetic study versus our tablet this quarter. The PK data should it show equivalents to be sufficient to advance the sublingual formulation to the clinic. With respect to our ex U.S. partnership, CMS Pharma continues to advance the regulatory process across multiple countries in Asia, and we anticipate 2 strategic product approvals in 2026.

From a financial perspective, the company’s operating spend of approximately [ $12 ] million reflects a deliberate investment in our commercial capabilities and in studies that support our positioning with health care providers and payers. I want to be direct about the way we’re thinking about our investment phase. Our net loss this quarter reflects the company’s scaling our efforts intentionally. We’re deploying capital against our highest return opportunities in the business. including expanding prescriber reach, building real-world evidence to support ZUNVEYL and unlocking additional payer access. These are investments that will drive the company to achieve operating profitability in 2027 and beyond, and we continue to remain on track with these targets.

Henry will now review the financials in detail, and Lauren will provide a comprehensive commercial update after Henry concludes his comments. Henry?

Henry Du: Thank you, Michael. Good afternoon, everyone. As I review our first quarter of 2026 results, please refer to today’s press release and 10-K — 10-Q filed this afternoon. For the first quarter of 2026, we generated total net product revenues of $3.5 million in ZUNVEYL. This compares to Q4 2025 net product revenues of $2.5 million, representing 40% sequential growth quarter-over-quarter. On a year-over-year basis, Q1 net product revenues were $347,000, representing only the final 2 weeks of March 2025 following our commercial launch, plus $2.6 million in licensing revenue from our CMS agreement. The trajectory from that initial quarter to $3.5 million in Q1 2026 illustrates the significant commercial progress ZUNVEYL has made in just 1-year of commercialization.

Total operating expenses, including cost of revenues, for Q1 2026 were approximately $11.6 million, reflecting our continued commercial infrastructure investment, taking into account a fully stepped 60-person customer-facing sales team expanded payer engagement capabilities, marketing sources and initiation of our RESOLVE clinical study. For context, Q4 2025 total operating expenses were $10.7 million and $6.3 million in Q1 of last year. The step-up in the aforementioned periods to Q1 2026 reflects the intentional investment decisions that Michael described. So scaling stills force spending on market reach and initiating studies that will generate the real-world be needed to accelerate the payer coverage and prescriber adoption. For Q1 2026, we reported a net loss of approximately $6.5 million or [ $0.30 ] basic loss per share.

This compares to a net loss of $1.7 million or $0.11 per share in Q1 2025. The year-over-year increase reflects the investments made in our commercial infrastructure, payer engagement and clinical programs, all of which are core to advancing ZUNVEYL’s long-term trajectory. Our core operating efficiency is also improving, and we view our current investment level as appropriate for this stage of growth. As of March 31, 2026, company had approximately $54.2 million in cash and cash equivalents compared to $66 million at December 31, 2025. The company maintained a debt-free balance sheet. We continue to believe our current capital position is sufficient to fund operations, sustains ZUNVEYL’s commercialization and advance our clinical programs as well as reaching operating profitability in 2027.

While we are not providing revenue guidance at this time, we are reiterating our full year 2026 operating expense guidance of approximately $54 million to $58 million. This is unchanged from our prior guidance. We expect Q2 spending to increase modestly related to Q1 as RESOLVE ramps and our education programs accelerate. But the overall 2026 spending profile remains in line with our plan. We believe this reflects investments needed to support our commercial operations, 3 real-world clinical studies, payer engagement programs and advancement of our single formulation. With that, I will now turn the call over to Lauren to discuss commercial progress. Lauren?

Lauren D’Angelo: Thank you, Henry. I’m pleased to provide a detailed update on our Q1 2026 commercial performance. This was a quarter of meaningful execution across prescriber adoption, nursing home penetration and payer engagement and the data tell a compelling story of durable accelerating commercial traction. Let me start with our adoption metrics. In Q1, the commercial team reached approximately 7,900 total health care providers and called on approximately 3,762 prescribers a 93% increase over the prior quarter. This reflects the expanded reach of our now fully stepped 60-person customer-facing field team. HCP writers categorized as prescribers who have written at least 1 ZUNVEYL bill prescription grew 23% quarter-over-quarter to 1,060.

This represents approximately a 28% conversion rate from prescribers called on, a strong indicator of early commercial efficiency. We entered 2026 with the goal of reaching approximately 2,000 prescribers and our Q1 growth puts us on a strong trajectory for us to reach this goal. 795 of our 1,060 active writers or approximately 75% have placed repeat prescriptions. Importantly, this implies not just adoption but sustained utilization with each writer averaging approximately 5 to 6 prescriptions in the quarter. Homes with ZUNVEYL prescriptions grew 25% quarter-over-quarter to 914, this represents approximately 36% penetration of the facilities we called on with each active home averaging over 6 prescriptions in the quarter. 736 have placed repeat orders an 81% repeat rate at the facility level.

This is what durable adoption looks like. We called on 2,502 unique nursing homes in Q1, 26% more than in Q4, and we brought 110 new homes on board in March alone. Our highest single month new account total since launch. Q1 monthly trajectory is notable because it captures how our commercial momentum built through the quarter. In March, we delivered 2,321 bottles, our highest demand month since launch. This represents a roughly 29% increase over February and establishes a clear exit velocity as we enter Q2. Total bottles dispensed in Q1 were 6,054, a 23% increase over Q4’s 4,941 bottles. Across both prescribers and facilities, we are seeing consistent patterns of depth, not just breadth of adoption conversion rates, repeat utilization and prescriptions per account all point to a product that is not only being tried, but actively integrated into clinical practice.

We believe our ongoing real-world evidence programs will further reinforce these adoption trends over time. Beacon, converge and RESOLVE are designed to generate clinically relevant data in the settings where Alzheimer’s patients are actually treated, including long-term care and outpatient practice. Importantly, we expect these studies to provide meaningful promotional value for our commercial organization by supporting peer-to-peer education, strengthening payer discussions and increasing physician confidence around tolerability, polypharmacy management, behavioral outcomes and caregiver burden. We believe these data sets will become increasingly important tools as we continue expanding market access and prescriber utilization. During the quarter, we also implemented a 6% price increase for ZUNVEYL to $869.36.

We believe our ability to take pricing reflects growing confidence in the product’s value proposition, strong underlying demand trends and the continued depth of adoption we are seeing both prescribers and facilities. Payer access remains both our most significant near-term friction point and our most significant near-term opportunity. Importantly, we view this as a timing dynamic rather than a demand contra given the strength of our underlying prescription growth and repeat utilization trends. Our team continued active engagement with national and regional plans throughout Q1. To provide context on where we stand, we have Medicare D contracts in place with 2 major PBMs representing approximately 45 million covered lives. Both contracts carry no prior authorization requirements for ZUNVEYL.

This positions us favorably from a policy standpoint once implementation expands across downstream plans. Implementation across downstream plan clients is currently at approximately 16% of the total contracted book of business. When our reimbursement team helped support the prior authorization submission process, our approval rate is approximately 89%. The path to broader implementation is a waiting and seeing game typical of an access curve. As is common with newly launched therapies, plans are monitoring early utilization trends before fully activating formulary access across their networks. We expect contracts to begin gaining meaningful traction in Q2 and Q3 and we are working to accelerate this through our real-world evidence program and our expanded payer engagement team.

We are seeing small pockets of improvement across specific plans and regions, and our focus now is on scaling those early wins into broader system-wide adoption across large national plans. Our full sales team of 60 customer-facing representatives and management is now in place and productive. With the team fully deployed, we are now focused on driving productivity and conversion efficiency across territories. We are also leveraging AI-enabled commercial analytics and targeting tools to help optimize territory execution, identify high-value prescriber opportunities and improve the efficiency of our field engagement efforts. We believe these capabilities will allow us to scale our commercial organization thoughtfully while maximizing return on investment.

In Q1, we completed our speaker training for 48 key [ 10 ] union leaders and have begun rolling out our peer-to-peer educational program, an important tool for converting curious prescribers to confident on ZUNVEYL writers. We presented new clinical data at the American Association of Geriatric Psychiatrists Conference in April, and we are presenting at the Neuroscience Education Institute Spring Congress in May. These engagements are key components of our strategy to reinforce clinical confidence and expand awareness among high-value prescribers. These conference appearances combined with our digital educational programs and virtual webinar series represent a comprehensive multichannel approach to building scientific credibility and prescriber confidence for ZUNVEYL.

In summary, Q1 2026 as a quarter of deliberate, well-executed commercial progress. We are seeing strong underlying demand high repeat utilization and increasing depth of adoption across both prescribers and facilities. We are growing our prescriber base, deepening facility penetration, building a compelling evidence base and making steady progress on payer access. As access expands, we believe these fundamentals position us well for continued acceleration. I’ll now hand it back to Michael for closing remarks.

Michael McFadden: Thank you, Lauren. Let me briefly summarize what I believe are the key takeaways for the company for Q1 2026. First, ZUNVEYL is growing. We delivered 40% sequential growth in revenues from Q4 to Q1 and our highest bottle count since launch was in March. We continue to grow and our commercial trajectory is accelerating. Secondly, our clinical programs are advancing ahead of schedule. Beacon will complete enrollment this quarter. We expect top line data reported no later than early Q3. RESOLVE and CONVERGE will initiate this quarter. And by the end of 2026, we’ll have 2 real-world evidence data sets and hand a powerful foundation for our payer coverage expansion and also to build prescriber confidence. Third, we’re scaling with discipline.

Our Q1 operating spend of approximately $12 million, reflects [indiscernible] investment and the resources needed to win in our market, and we’re building very deliberately. Full year 2026 expense guidance of $54 million to $58 million is unchanged, and we remain on track for operating profitability in 2027. And fourth, our organization is stronger than ever. Our full fill team is in place. We’ve added meaningful payer and marketing talent. We’ve strengthened our Board. We’re building this company to win. So we’re excited about the balance of 2026. Our pipeline of near-term catalysts, BEACON data, CONVERGE data, both in Q3, sublingual PK data in Q3, continued ex U.S. milestones that will advance an ongoing payer progress. All of these things give us encouraging signs that our platform we built for ZUNVEYL, we’ll continue to reap rewards.

Operator, with that comment, we’ll now take questions.

Q&A Session

Operator: [Operator Instructions] Our first question comes from the line of Raghuram Selvaraju with H.C. Wainwright.

Unknown Analyst: This is Jan sitting in for Ram. I have a few questions. So the first is — would you be able to tell me if there’s been any notable changes in prior authorizations or step edit requirements over the past several months?

Lauren D’Angelo: Sure. Thanks for the question. I would say that there has not been a noticeable change in terms of an increase or decrease in the number of prior authorizations since launch, really — what we have seen a change in is our approval rate. So when our reimbursement team is able to support the prior authorization with the additional resources and just experience over the past year, we know what it takes to get a prior authorization approved. So you will see that we have anywhere — we say 89%, but sometimes higher from an approval rate for those prior authorizations. But no, we haven’t seen any really hard restrictions put in place in terms of step edits or prior authorization. I would say it’s pretty consistent over the last 3 quarters.

Unknown Analyst: Got it. And for my next question, I was wondering if you’d be able to tell me, are there any anticipated to be key visibility milestones that would be reached in the development of the film formulation over the remainder of 2026?

Michael McFadden: Yes. So we — that’s a great question. We are advancing with a PK study comparing our sublingual formulation to our tablet formulation. Should that data show equivalents, we will submit an IND to FDA for that sublingual program, which we believe, if approved, would move us to clinic, and we anticipate delivering the IND the latter part of the year.

Unknown Analyst: I have one more if there’s time. So what will be the cadence of data released from the ongoing and planned clinical studies of ZUNVEYL in the post-approval context?

Michael McFadden: Yes, another good question. So we completing enrollment with Beacon much earlier than we anticipated. We anticipated enrollment and top line data reported in the latter part of Q4. We’re completing enrollment this quarter. So we have to analyze the data and review our tables, and we anticipate that we’ll be able to release top line data from BEACON no later than early Q3. So well ahead of expectations, significance of the study is that this is one of the only data sets in long-term care, the segment that we participate in that will be published and will be executed from a study standpoint. The data should give us insights in ZUNVEYL efficacy for both cognition and behavioral response. It will give us data on tolerability for ZUNVEYL, and it will also give us data on polypharmacy.

The use of use increase or decrease of other agents when ZUNVEYL is utilized in therapy. So a gold mine of data and I anticipate there’ll be a lot of publication opportunities for BEACON. CONVERGE initiates this quarter. It’s a retrospective data analysis. So the work will be done rather efficiently, and we anticipate top line data from CONVERGE will occur in Q3 of 2026. So we’ll have our first segment of that data complete in Q3, and there’ll be additional segments that will follow. All of those data sets will be publishable and we’ll be submitting for publication with both CONVERGE and BEACON. RESOLVE initiates in Q2. We don’t expect that RESOLVE completely in 2026. It will complete the Q2 of 2027.

Operator: Our next question comes from the line of Chase Nickerbacher with Craig Hallum Capital Group.

Unknown Analyst: Maybe just 2 for me. I’ll ask them both upfront. So you spoke to March acceleration. Helpful to understand the cadence through the quarter. Can you just maybe speak to what extent you’ve seen that acceleration that trend continue into April? Kind of what you kind of see as driving it in March and again, what you’re seeing in April, are you seeing your kind of lower tenure reps starting to be more productive, et cetera. And then just second, your kind of customer metrics are growing at a similar kind of rate as volume if we look sequentially. How should we be kind of thinking about the deepening of prescribing patterns? Do you have any cohorts that are mature enough over the course of the last couple of quarters that you can kind of see how that trend develops as far as a prescriber that’s been writing for 2 or 3 quarters and how the deepening of their prescribing patterns occurs over time.

Lauren D’Angelo: Sure. So 2 really good questions. So I’ll start with the first one. Yes, March was our biggest month since launch. We saw the highest number of bottles dispensed we are seeing that continued acceleration into April. I think when we look at these key foundational factors that we put into place, we’ve — we completed the increase in our sales force or customer-facing sales force that really completed in the early part of this quarter. We put our speakers in place, our speaker program execution. We’ve made some adjustments in our payer team and our marketing team to bring on just more power as we approach the market. And so with each passing day, we are seeing continued acceleration, and we expect that acceleration to continue in a very positive momentum.

As for the way that we’re segmenting the market. So you’re absolutely right. We’ve talked a lot about that over the past year. Typically, a provider will try the product, it’s a very vulnerable population in the long-term care community. So they’ll try a couple of patients, they wait a month, 2, sometimes 3 months to see how the drug performs, and then they’ll add additional patients on to ZUNVEYL. So at this point, we are very in tune with that adoption pattern, how fast it takes the physician to move from 1 tier to the loyalist here, if you want to call them that. And what we’re seeing is very, very positive. So we’re — all the entire commercial team is focused on the segment of physicians to have tried. They’ve got a few patients on and we can move them further to the right, and that’s exactly how we’re approaching the market.

So we definitely understand the pattern. We continue to see more and more physicians move into that loyalist bucket, and we’ll continue to execute our tactics with a focus on that type of segmentation. I don’t know if that answers your question, but that’s kind of how we are actually focusing our tactics and our activity.

Unknown Analyst: It does. Very helpful.

Operator: Your next question comes from the line of David Storms with Stonegate.

David Storms: Lauren, I wanted to start maybe with the AI analytics comment that you made. Could you maybe a little more color about how far along this is and maybe any early results here?

Lauren D’Angelo: Sure. No, absolutely. Our team — Michael and I, from the very beginning have really tried to be out in the forefront as it relates to AI capabilities. And it’s not that hard to implement. AI tools in today’s environment. So we have actually started applying AI tools across the board, not just commercial but really across the entire company. Most of our team members are using AI on a daily basis. But as it relates to our commercial opportunity, how we’re approaching the market, how we’re segmenting the market, that’s really where we’re leveraging the AI tools. As you can imagine, we have a ton of data that is constantly coming in on a daily basis, and we’re able to leverage those tools to really decipher the key information that we need to turn around and approach the market with a very specific tactic.

So we’ve used it across the board from a targeting perspective. We’ve used it across the board for a segmenting perspective. We’re using it daily just to be more efficient from an administrative perspective across the team. So we really are at the point — we’re not all the way where we’re — I would say we’re 100% AI, but we have definitely probably adopted AI, and we’re using it to be more efficient, more targeted, make sure we’re calling on the right customers, making sure that we’re delivering the right message to the right customer. And so I think we are actually pretty far above most companies in our AI technical capabilities.

David Storms: Understood. Maybe just a quick modeling question as well. The R&D call out, it’s going to be a little bit higher in Q2. Should we expect this to kind of ramp with the study throughout the year? Are there any variables that would make this a little more lumpy?

Henry Du: Yes. I think it will depend on enrollment with RESOLVE. RESOLVE is the majority of our R&D spend in 2026. We’re initiating first patient in Q2, we should see some acceleration in Q3, Q4. I would think that will be later, David, but we have a lot of sites that will be enrolling in Q3. So it will depend on how fast they begin to enroll patients. So it could be a little bit of bump — there could be a little bumpiness in Q3, Q4.

David Storms: That’s perfect. And maybe one more for me. Michael, you mentioned in your prepared remarks that you have a new TBI patent recognizing that there’s a long-term project for you guys. Is there just maybe any more information you can give us here about kind of what the outlook is for this channel?

Michael McFadden: It’s an extremely exciting opportunity for the company, $14 billion market opportunity, affects patients from teenage years all the way to 65. It’s where the majority of the patients reside, so across all patient age ranges. No approved product to treat TBI, and there’s nothing really off label that shoes that works to treat the cognitive impairment that the company is about 1/2 of concussion or TBI patients. So we’re really excited about our early phase data. We’ll roll that out this year and the fact that our drug demonstrated significant cognitive effects, neurogenesis, a decrease in inflammation, mobility improvements, et cetera. That data is very good preclinical data it has — we’ll see if it translates into the clinic, but we’re most excited about advancing that program.

From a clinical next steps. We plan to use our sublingual formulation for TBI. We have met with the agency on pre-IND program, and we need — we will run a tox study, a 12-week tox study this year. We believe that is all the preclinical work left are needed for that program to advance an IND, which will move us to the clinic.

David Storms: That’s perfect.

Operator: This now concludes our question-and-answer session. I would like to turn the floor back over to Michael McFaddenMadon for closing comments.

Michael McFadden: Thank you, operator. Thanks everyone for joining us this afternoon. We feel like the company is executing both with our KPIs, our clinical steady expertise to support our payers and health care professionals, and we encourage everybody to continue to watch the company as it continues to execute in Q2. If those attending this call or reading the transcript have questions, feel free to reach out to our IR group, and we’re happy to answer a follow-up question set results following this call. Thank you for attending.

Operator: Ladies and gentlemen, thank you for your participation. This does conclude today’s teleconference. You may disconnect your lines, and have a wonderful day.